CEL-SCI reports positive FDA meeting for Multikine approval; Canada possible 2024

CEL SCI CORP

FDA acknowledged need for improved head/neck cancer treatments; CEL-SCI preparing further development plan.
Multikine showed 14.1% absolute OS benefit in lower-risk ITT subjects; 15.2% tumor response in 3 weeks.
Health Canada advised NOCC application; commercialization in Canada could begin as early as 2024.
Upcoming scientific advice meetings with EMA and MHRA in fall 2023.
CEL-SCI plans to file NOCC application in Canada later this year/early next year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.